<DOC>
	<DOCNO>NCT00442312</DOCNO>
	<brief_summary>This study evaluate efficacy safety Combigan ophthalmic solution combination Latanoprost therapy swiched Latanoprost monotherapy patient Glaucoma ocular hypertension . Hypothesis : 1 . Combigan Ophthalmic Solution provide addition IOP loweringwhen combine Latanoprost . 2 . The treatment Combigan Ophthalmic Solution acceptable safety profile , measure ocular systemic safety parameter .</brief_summary>
	<brief_title>Combigan Ophthalmic Solution ( Brimonidine 0.2 % Timolol 0.5 % ) With Latanoprost Compared With Latanoprost Monotherapy</brief_title>
	<detailed_description>The purpose study comparethe efficacy safety Ophthalmic Solution combination Latanoprost therapy swiched Latanoprost monotherapy patient Glaucoma ocular hypertension . The study open label , prospective , multi-centered patient swiched Latanoprostmonotherapy combination therapy Latanoprost Combigan Ophthalmic Solution .</detailed_description>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Latanoprost</mesh_term>
	<mesh_term>Brimonidine Tartrate</mesh_term>
	<mesh_term>Timolol</mesh_term>
	<mesh_term>Brimonidine Tartrate , Timolol Maleate Drug Combination</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>1 . Male female , legal age consent . 2 . Diagnosis ocular hypertension ( OHT ) glaucoma ( incl . open angle glaucoma , chronic angle closure glaucoma , exfoliative glaucoma , pigmentary glaucoma pseudophakic glaucoma ) require administration IOP lower eye drop . 3 . Written inform consent obtain . 4 . The patient understand study instruction , willing able comply schedule visit treatment . 5 . Patient administer latanoprost eye drop monotherapy affect eye ( ) least 12 week accord approve product labeling . 6 . Patient ’ Day 0 IOP &gt; 18 mm Hg propose study eye/s establish latanoprost therapy . 7 . Patients use COMBIGAN® Ophthalmic Solution past must discontinue use medication due adverse event due lack efficacy . 8 . Day 0 : negative urine pregnancy test female childbearing potential . 1 . .Uncontrolled systemic disease ( e.g. , hypertension , diabetes ) . 2 . .Females pregnant , nursing , plan pregnancy , females childbearing potential use reliable mean contraception . A female consider childbearing potential unless postmenopausal , without uterus and/or ovary , tuballigation . 3 . .Known allergy hypersensitivity study medication component . 4 . .Anticipated alteration exist chronic therapy agent could substantial effect IOP ( include , necessarily limited systemic adrenergic agent include betaadrenergic block agent [ e.g. , propanolol , metoprolol , nadolol , timolol atenolol ] ) , substantial interaction study medication , interaction study outcome . 5 . .Corneal abnormality would preclude accurate IOP reading applanation tonometer . 6 . .Any active ocular disease glaucoma ocular hypertension ( e.g. , uveitis , ocular infection , severe dry eye ) . However , patient chronic mild blepharitis , cataract , agerelated macular degeneration , background diabetic retinopathy enrol discretion investigator . 7 . .Required chronic use ocular medication study study medication . Occasional use artificial tear topical decongestant and/or antihistamine acceptable . Use within 24 hour schedule study visit prohibit . 8 . .Ocular surgery within past 3 month . 9 . .Current enrolment investigational drug device study participation study within 30 day entry study . 10 . .Patient condition situation investigator 's opinion may put patient significant risk , may confound study result , may interfere significantly patient 's participation study , 11 . .Day 0 Significant ocular irritation .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2007</verification_date>
	<keyword>Combigan</keyword>
</DOC>